Abel Mendez, NP
Family · San Antonio, TXNPI 1366896888
Payments from drug & device makers
Across 109 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$379
- Viiv Healthcare Company$282
- Grifols USA, LLC$194
- Gilead$185
- Theratechnologies Inc.$160
- Octapharma USA, Inc.$145
- plus $983 from 17 others
What the payments were for
- Speaking & faculty fees$191%
- Food & beverage$2,26997%
- Education$402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 20 | $379 |
| Viiv Healthcare Company | 13 | $282 |
| Grifols USA, LLC | 9 | $194 |
| Gilead | 9 | $185 |
| Theratechnologies Inc. | 9 | $160 |
| Octapharma USA, Inc. | 7 | $145 |
| Shionogi Inc | 6 | $135 |
| Karyopharm Therapeutics Inc. | 1 | $125 |
| CSL Behring | 7 | $119 |
| Aimmune Therapeutics, Inc. | 5 | $119 |
| AbbVie | 5 | $111 |
| Napo Pharmaceuticals Inc | 3 | $57 |
| Johnson & Johnson | 2 | $40 |
| Insmed, Inc. | 2 | $39 |
| Merck | 2 | $34 |
| ADMA Biomanufacturing LLC | 1 | $31 |
| Redhill Biopharma Inc. | 2 | $31 |
| Pharming Healthcare, Inc. | 1 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $25 |
| Melinta Therapeutics, LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Mayne Pharma Commercial LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPOVIO$125
How this compares
$2,328 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefepime Hcl | 65 | $13,412 |
| Daptomycin | 61 | $13,393 |
| ErtapenemErtapenem Sodium | 42 | $12,997 |
| Vancomycin Hcl | 63 | $6,799 |
| Meropenem | 36 | $4,358 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 34 | $4,292 |
| Cefazolin Sodium | 52 | $3,620 |
| CeftriaxoneCeftriaxone Sodium | 61 | $2,292 |
Paid to pharmacies, not to this prescriber.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Ayoade AvworoSan Antonio$111K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.